Evidence map›Paper›PMID 34085236›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2021

An Informatics Pipeline for Profiling and Annotating RNA Modifications.

Qi Liu, Xiaoqiang Lang, Richard I Gregory

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. RNA modifications and their role in gene expression.Frontiers in molecular biosciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Qi LiuStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA. qi.liu2@childrens.harvard.edu.
Xiaoqiang LangPrecision Medicine Research Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Richard I GregoryStem Cell Program, Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.
Boston Children's Hospital · USSichuan University · CN

Funding

Role of the Epitranscriptome in CancerR35CA232115 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GREGORY, RICHARD I. · 2019 to 2025
$7.2M
Role of METTL3 and the m6A Epitranscriptome in cancerR01CA233671 · NCI · BOSTON CHILDREN'S HOSPITAL · PI GREGORY, RICHARD I., KIM, CARLA F. · 2020 to 2024
$3.2M
NCI NIH HHS R01 CA233671NCI NIH HHS R35 CA232115
6 · The paper itself

Abstract

While over 150 distinct types of chemical modifications are known to occur on various cellular RNAs and can be dynamically controlled, the function of most of these modifications remains poorly defined. Collectively, these RNA modifications have been recently termed the "epitranscriptome". Identification and annotation of individual RNA modifications throughout the transcriptome are key for studying the role of the epitranscriptome in the regulation of gene expression and for elucidating the functional relevance of particular RNA modifications in diverse physiological and disease processes. In this protocol, we demonstrate how to identify and annotate RNA modifications based on the informatic analysis of methylated RNA immunoprecipitation and sequencing (MeRIP-seq) data, using RNAmod, a convenient one-stop online interactive platform for the annotation, analysis, and visualization of mRNA modifications.

Indexed as

Cell Line, TumorHep G2 CellsHumansInformaticsRNARNA Processing, Post-TranscriptionalSequence Analysis, RNATranscriptomeRNAAnnotationEpitranscriptomeIdentificationMeRIP-seqRBPRNA-binding proteinRNA modificationSoftwareToolWeb server

Identifiers

PMID34085236
OpenAlexW3164797408

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.